Previous studies have identified GLUT9 and URAT1, involved in uric acid reabsorption, and OAT1 and OAT3, involved in uric acid excretion, as potential therapeutic targets for hyperuricemia [10,22,23]. Here, SLC22A6 is linked to hyperuricemia.